Effectiveness of Primary Anti-Aspergillus Prophylaxis during Remission Induction Chemotherapy of Acute Myeloid Leukemia

dc.creatorGomes, Marisa Z. R.
dc.creatorJiang, Ying
dc.creatorMulanovich, Victor E.
dc.creatorLewis, Russell E.
dc.creatorKontoyiannis, Dimitrios P.
dc.date2015-07-03T12:34:38Z
dc.date2015-07-03T12:34:38Z
dc.date2014
dc.date.accessioned2023-09-26T22:02:51Z
dc.date.available2023-09-26T22:02:51Z
dc.identifierGOMES, Marisa Z. R. et al. Effectiveness of Primary Anti-Aspergillus Prophylaxis during Remission Induction Chemotherapy of Acute Myeloid Leukemia. Antimicrobial Agents and Chemotherapy, v.58, n.5, p.2775-2780, may 2014.
dc.identifier0066-4804
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/11068
dc.identifier10.1128/AAC.01527-13
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8874481
dc.descriptionAlthough antifungal prophylaxis is frequently administered to patients with acute myeloid leukemia (AML) during remissioninduction chemotherapy (RIC), its impact on reducing invasive fungal infections (IFIs) outside clinical trials is rarely reported. We performed a retrospective observational study to identify risk factors for development of IFIs (definite or probable, using revised European Organization for Research and Treatment of Cancer [EORTC] criteria) and all-cause mortality in a cohort of 152 AML patients receiving RIC (2009 to 2011). We also compared rates of IFI and mortality in patients who received echinocandin versus anti-Aspergillus azole (voriconazole or posaconazole) prophylaxis during the first 120 days of RIC. In multivariate analysis, clofarabine-based RIC (hazard ratio [HR], 3.5; 95% confidence interval [CI], 1.5 to 8.3; P 0.004) and echinocandin prophylaxis (HR, 4.6; 95% CI, 1.8 to 11.9; P 0.002) were independently associated with higher rates of IFI rates during RIC. Subsequent analysis failed to identify any malignancy- or chemotherapy-related covariates linked to echinocandin prophylaxis that accounted for the higher rates of breakthrough IFI. Although the possibility of other confounding variables cannot be excluded, our findings suggest that echinocandin-based prophylaxis during RIC for AML may be associated with a higher risk of breakthrough IFI.
dc.formatapplication/pdf
dc.languageeng
dc.publisherAmerican Society for Microbiology
dc.rightsopen access
dc.subjectProfilaxia
dc.subjectAspergillus
dc.subjectMyeloid Leukemia
dc.subjectChemotherapy
dc.subjectPrimary Anti-Aspergillus Prophylaxis
dc.subjectAspergillus
dc.subjectLeucemia Mieloide
dc.subjectQuimioterapia
dc.titleEffectiveness of Primary Anti-Aspergillus Prophylaxis during Remission Induction Chemotherapy of Acute Myeloid Leukemia
dc.typeArticle


Este ítem pertenece a la siguiente institución